New data confirms what neurological literature has long suggested: small cell lung cancer accounts for approximately 50% of all paraneoplastic neurologic syndromes, making it the single most common underlying malignancy in these cases. A recent case report published in the Canadian Medical Association Journal reinforces this striking epidemiological pattern.
While breast cancer (20%), ovarian cancer (15%), and Hodgkin lymphoma (10%) contribute to paraneoplastic syndromes, small cell lung cancer’s dominance reflects both its aggressive biology and its propensity to trigger immune cross-reactivity with neural tissue. These syndromes, though rare—affecting approximately 1 in 10,000 cancer patients—demand clinical vigilance.
The clinical implication is straightforward: when a patient presents with progressive neurological symptoms of unclear etiology, early antibody testing and targeted cancer screening, particularly for small cell lung cancer, can identify malignancy months before conventional imaging. This early detection strategy significantly improves patient outcomes and enables timely therapeutic intervention.
Read the full article on GMJ Newsroom.
Was this article helpful?
